GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00322594 | Thyroid | PTC | methylation | 146/5968 | 364/18723 | 4.99e-04 | 3.26e-03 | 146 |
GO:004511616 | Thyroid | PTC | protein neddylation | 13/5968 | 18/18723 | 5.21e-04 | 3.37e-03 | 13 |
GO:004876215 | Thyroid | PTC | mesenchymal cell differentiation | 99/5968 | 236/18723 | 6.72e-04 | 4.22e-03 | 99 |
GO:003210316 | Thyroid | PTC | positive regulation of response to external stimulus | 167/5968 | 427/18723 | 8.31e-04 | 5.13e-03 | 167 |
GO:00985869 | Thyroid | PTC | cellular response to virus | 41/5968 | 84/18723 | 8.84e-04 | 5.40e-03 | 41 |
GO:003017810 | Thyroid | PTC | negative regulation of Wnt signaling pathway | 74/5968 | 170/18723 | 8.99e-04 | 5.48e-03 | 74 |
GO:00603387 | Thyroid | PTC | regulation of type I interferon-mediated signaling pathway | 21/5968 | 36/18723 | 9.36e-04 | 5.68e-03 | 21 |
GO:00434145 | Thyroid | PTC | macromolecule methylation | 127/5968 | 316/18723 | 1.02e-03 | 6.07e-03 | 127 |
GO:00324796 | Thyroid | PTC | regulation of type I interferon production | 45/5968 | 95/18723 | 1.13e-03 | 6.63e-03 | 45 |
GO:00326066 | Thyroid | PTC | type I interferon production | 45/5968 | 95/18723 | 1.13e-03 | 6.63e-03 | 45 |
GO:00517753 | Thyroid | PTC | response to redox state | 11/5968 | 15/18723 | 1.19e-03 | 6.84e-03 | 11 |
GO:0031507 | Thyroid | PTC | heterochromatin assembly | 22/5968 | 39/18723 | 1.32e-03 | 7.47e-03 | 22 |
GO:00516077 | Thyroid | PTC | defense response to virus | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
GO:01405467 | Thyroid | PTC | defense response to symbiont | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
GO:00607597 | Thyroid | PTC | regulation of response to cytokine stimulus | 70/5968 | 162/18723 | 1.54e-03 | 8.58e-03 | 70 |
GO:0007043111 | Thyroid | PTC | cell-cell junction assembly | 64/5968 | 146/18723 | 1.56e-03 | 8.63e-03 | 64 |
GO:00434918 | Thyroid | PTC | protein kinase B signaling | 88/5968 | 211/18723 | 1.59e-03 | 8.81e-03 | 88 |
GO:00107175 | Thyroid | PTC | regulation of epithelial to mesenchymal transition | 46/5968 | 99/18723 | 1.66e-03 | 9.13e-03 | 46 |
GO:003235518 | Thyroid | PTC | response to estradiol | 62/5968 | 141/18723 | 1.67e-03 | 9.16e-03 | 62 |
GO:00305209 | Thyroid | PTC | intracellular estrogen receptor signaling pathway | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F7 | SNV | Missense_Mutation | novel | c.308N>A | p.Ser103Tyr | p.S103Y | P08709 | protein_coding | tolerated(0.17) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.729N>G | p.Ile243Met | p.I243M | P08709 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | novel | c.1132N>A | p.Gly378Arg | p.G378R | P08709 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
F7 | SNV | Missense_Mutation | rs749760143 | c.973N>A | p.Glu325Lys | p.E325K | P08709 | protein_coding | tolerated(0.05) | probably_damaging(0.933) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
F7 | insertion | Frame_Shift_Ins | novel | c.731_732insGGGAAAATGGGCAGGTCAGC | p.Asn244LysfsTer28 | p.N244Kfs*28 | P08709 | protein_coding | | | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | insertion | Frame_Shift_Ins | novel | c.757_758insGCAA | p.His253ArgfsTer29 | p.H253Rfs*29 | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | insertion | In_Frame_Ins | novel | c.759_760insCCCAAGGCCGAATTGTGGGGGGCAAGG | p.His253_Cys254insProLysAlaGluLeuTrpGlyAlaArg | p.H253_C254insPKAELWGAR | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | P08709 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
F7 | SNV | Missense_Mutation | novel | c.348N>C | p.Gln116His | p.Q116H | P08709 | protein_coding | deleterious(0.02) | probably_damaging(0.961) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.160N>A | p.Val54Ile | p.V54I | P08709 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Vatreptacog alfa (activated) | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Factor viia | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Recombinant factor VIIa PEGylated liposomal | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | F-7TG | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | BAX-817 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178103166 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | CB-813 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Activated recombinant FVII-albumin fusion protein | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166701 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Eptacog alfa intravenous | | |